Holen Sie sich die Stockscreener-App
0.4678
5.46%
-0.027
Handel nachbörslich:
.48
0.0122
+2.61%
Schlusskurs vom Vortag:
$0.4948
Offen:
$0.491
24-Stunden-Volumen:
290.44K
Relative Volume:
1.61
Marktkapitalisierung:
$50.40M
Einnahmen:
$1.29M
Nettoeinkommen (Verlust:
$-29.87M
KGV:
-1.2994
EPS:
-0.36
Netto-Cashflow:
$-14.70M
1W Leistung:
-10.07%
1M Leistung:
-4.14%
6M Leistung:
-38.77%
1J Leistung:
-46.69%
1-Tages-Spanne:
$0.46
$0.498
1-Wochen-Bereich:
$0.46
$0.535
52-Wochen-Spanne:
$0.42
$0.90
VolitionRX Ltd Stock (VNRX) Company Profile
Firmenname
VolitionRX Ltd
Sektor
Branche
Telefon
646 650 1351
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Vergleichen Sie VNRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.4678 | 50.40M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
428.95 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.61 | 136.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
509.13 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.42 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.68 | 25.29B | 15.50B | 1.33B | 2.16B | 7.34 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Eingeleitet | Maxim Group | Buy |
| 2018-05-14 | Bestätigt | The Benchmark Company | Buy |
| 2016-09-07 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-02-01 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten
VolitionRx (VNRX) Expected to Announce Quarterly Earnings on Monday - Defense World
VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock - Barchart.com
VolitionRx Updates Progress Of Nu.Q NETs Test Adoption - marketscreener.com
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
VolitionRx enters new sales agreement, terminates old one - Investing.com Australia
VolitionRx enters new sales agreement, terminates old one By Investing.com - Investing.com South Africa
VolitionRX Ltd (AMEX: VNRX): An Enticing Stock To Watch - stocksregister.com
Insider Buying: Reynolds Cameron John, VolitionRX Ltd [VNRX] President and CEO invested 181,818 shares - knoxdaily.com
VolitionRx (NYSE:VNRX) Now Covered by StockNews.com - The AM Reporter
H.C. Wainwright maintains buy on VolitionRX with $2.50 target By Investing.com - Investing.com South Africa
VolitionRx (NYSE:VNRX) Coverage Initiated at HC Wainwright - The AM Reporter
What is HC Wainwright’s Estimate for VolitionRx Q1 Earnings? - Defense World
VolitionRX stock holds as Benchmark maintains rating - Investing.com Australia
VolitionRx (NYSE:VNRX) Now Covered by Analysts at HC Wainwright - Defense World
VolitionRX stock holds as Benchmark maintains rating By Investing.com - Investing.com South Africa
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
HC Wainwright Initiates VolitionRx With Buy Rating, $2.50 Price Target - marketscreener.com
VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
VolitionRx Moves to Register Warrant Shares on New Form By Investing.com - Investing.com South Africa
VolitionRx Moves to Register Warrant Shares on New Form - Investing.com
VolitionRx Limited (AMEX:VNRX) Q4 2024 Earnings Call Transcript - Insider Monkey
VolitionRx Ltd. Earnings Call Highlights Growth and Challenges - TipRanks
VolitionRX Ltd (VNRX) Reports Q4 EPS of -0.06, Revenue Surges to $1.2 Million, Exceeding Estimates - GuruFocus
VolitionRx (VNRX) Sees Strong Growth with Doubling of Nu.Q Vet T - GuruFocus
Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024 - Investing.com India
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances - Yahoo Finance
VolitionRx Limited Reports Strong 2024 Financial Results - TipRanks
Volitionrx Ltd earnings missed, revenue fell short of estimates - Investing.com
Volitionrx Ltd earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024 By Investing.com - Investing.com UK
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update - Financial Times
A Look Ahead: VolitionRX's Earnings Forecast - Benzinga
Volition Announces Two Poster Presentations At Esmo's European Lung Cancer Congress 2025 - MarketScreener
Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Canada
VolitionRx CEO Cameron Reynolds acquires $99,999 in stock - Investing.com
Volitionrx director Innes buys $99,999 in common stock - Investing.com
VolitionRx CEO Cameron Reynolds acquires $99,999 in stock By Investing.com - Investing.com UK
VolitionRx secures up to $2.3 million in direct offering By Investing.com - Investing.com South Africa
VolitionRx secures up to $2.3 million in direct offering - Investing.com India
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - Marketscreener.com
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - Yahoo Finance
D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRX Reports Positive Results of Automated Nu.Q Cancer Immunoassay Test in Development - Marketscreener.com
VolitionRx reports results from Nu.Q Cancer test - TipRanks
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - Yahoo Finance
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer - Yahoo Finance
Volitionrx announces pricing of public offering of 3.77 mln shares - Reuters
Volition Proudly Sponsors the 44th ISICEM Congress - Yahoo Finance
Finanzdaten der VolitionRX Ltd-Aktie (VNRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):